YL201

Phase 3Small molecule

MMediLink Therapeutics (Suzhou) Co., Ltd.

YL201 is one of 106 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

105

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Advanced Solid TumorsActive, not recruiting

Advanced Solid TumorRecruiting

Nasopharyngeal CarcinomaPhase 3

Active, not recruiting

Small Cell Lung CancerPhase 3

Active, not recruiting

Advanced Solid TumorsPhase 1

Active, not recruiting

Advanced Solid TumorPreclinical

Recruiting

Competition

Competitive Landscape

598 competitors in Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

34 2

Gemzar

Johnson & Johnson

Phase 3

26 3

Camptosar

Pfizer

Phase 3

26 4

Keytruda

Merck & Co.

Phase 3

20 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

98 6

Vepesid

Opdivo

16 8

Yervoy

Bristol-Myers Squibb

Phase 3

11 9

Tarlatamab-Dznl

Lynparza

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Advanced Solid Tumor

NCT05434234

Phase 1/2Recruiting

Advanced Solid Tumors

NCT07208773

Q2 2028

Phase 1/2Recruiting

Nasopharyngeal Carcinoma

NCT07258979

Q4 2028

Phase 1/2Active, not recruiting

Selected Advanced Solid Tumors

NCT06057922

Phase 3Recruiting

Nasopharyngeal Carcinoma

NCT06629597

Phase 3Not yet recruiting

Phase II

NCT07487896

Clinical

Trials by Indication[1]

Nasopharyngeal Carcinoma2 trials

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

Recruiting·MMediLink Therapeutics (Suzhou) Co., Ltd.·Phase 1/2·NCT07258979·202 enrolled

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

Recruiting·MMediLink Therapeutics (Suzhou) Co., Ltd.·Phase 3·NCT06629597·400 enrolled

Small Cell Lung Cancer2 trials

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

Recruiting· Amgen logo

Amgen·Phase 1·NCT06898957·200 enrolled

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

Recruiting·MMediLink Therapeutics (Suzhou) Co., Ltd.·Phase 3·NCT06612151·438 enrolled

Advanced Solid Tumors2 trials

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

Recruiting·MMediLink Therapeutics (Suzhou) Co., Ltd.·Phase 1/2·NCT07208773·260 enrolled

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Combination With Serplulimab With or Without Platinum-based Chemotherapy in Selected Subjects With Advanced Solid Tumors

Active, not recruiting·MMediLink Therapeutics (Suzhou) Co., Ltd.·Phase 1·NCT06394414·187 enrolled

Efficacy1 trial

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Recruiting·MMediLink Therapeutics (Suzhou) Co., Ltd.·Phase 2·NCT06241846·100 enrolled

Selected Advanced Solid Tumors1 trial

A Study YL201 in Patients With Selected Advanced Solid Tumors

Active, not recruiting·MMediLink Therapeutics (Suzhou) Co., Ltd.·Phase 1/2·NCT06057922·990 enrolled

3 more indications

Phase II1 trial

A Phase III Study Evaluating YL201 Versus ICC in 2L ESCC

Not yet recruiting·MMediLink Therapeutics (Suzhou) Co., Ltd.·Phase 3·NCT07487896·440 enrolled

Patients With Advanced Solid Tumors1 trial

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Not yet recruiting·MMediLink Therapeutics (Suzhou) Co., Ltd.·Phase 1/2·NCT07407933·118 enrolled

Advanced Solid Tumor1 trial

A Phase 1A/1B, Multicenter, Nonrandomized, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL201 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Recruiting·MMediLink Therapeutics (Suzhou) Co., Ltd.·Preclinical·NCT05434234·312 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for YL201. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — YL201 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for YL201. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — MediLink Therapeutics (Suzhou) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMediLink Therapeutics (Suzhou) Co., Ltd.

YL201

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Q4 2028

Trials by Indication[1]

Nasopharyngeal Carcinoma2 trials

Small Cell Lung Cancer2 trials

Advanced Solid Tumors2 trials

Efficacy1 trial

Selected Advanced Solid Tumors1 trial

Phase II1 trial

Patients With Advanced Solid Tumors1 trial

Advanced Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News